Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes.

ABSTRACT:

Background

First-line therapy for treatment of advanced urothelial carcinoma includes combination platinum-based chemotherapies, though resistance and long-term toxicity concerns to these regimens cause limitations in progression-free survival and overall survival. Maintenance treatment with an alternative agent such as the PD-L1 inhibitor, avelumab (Bavencio^®), after initial chemotherapy has been shown to prolong overall survival. The aim of this review is to provide a landscape clinical use of avelumab in the treatment of advanced urothelial carcinoma with a focus on patient selection and outcomes.

Methods

This review includes the most up to date phases and results from clinical trials published in peer-reviewed journals.

Results

Three studies were includ

SUBMITTER: Ten Eyck JE 

PROVIDER: S-EPMC8882657 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature